Africa: Which Covid-19 Vaccine Could Reach Developing Countries First?


Sumary of Africa: Which Covid-19 Vaccine Could Reach Developing Countries First?:

  • We asked experts to explain the key differences, and which could be the first to reach low-income countries Pharmaceutical companies are racing to produce a vaccine against COVID-19 to roll out in early 2021 but there are concerns poorer nations may get left behind..
  • Nations have already bought over 6 billion doses of vaccines yet to be approved for market but as of Nov 20 no low-income country has struck a direct deal, according to Duke University researchers..
  • We examine the front-running vaccines and ask experts if efforts to get them to the 22% of the world’s population – or 1.3 billion people – living in developing countries will succeed..
  • Anna Marriott, Health Policy Manager, Oxfam – “The number one challenge we’re seeing is the unprecedented scale of supply that is needed..
  • Taylor, Assistant Director of Programs, Duke Global Health Institute – “We need to focus on timing and equity of distribution..
  • it looks like high-income countries are likely to be well-covered by the first half of 2021 but low-income countries will still be waiting..
  • Roz Scourse, Policy Advisor, Medecins Sans Frontieres (MSF) – “Vaccine nationalism is a huge challenge for access to low and middle-income countries..
  • “Even if people in high income countries get access, if COVID is still circulating in other populations around the world we’re not going to see an end to the pandemic.”.
  • Taylor, Duke Global Health Institute – “In terms of efficient distribution in poorer countries, the Oxford/AstraZeneca vaccine appears to be the winner so far..
  • Scourse, MSF – “For Pfitzer and Moderna, there are a few different prices out there but basically, very high prices per dose which will definitely restrict their access to low and middle-income countries.”.
  • Sign up for free AllAfrica Newsletters Marriott, Oxfam – “I would rank AstraZeneca and Oxford first in terms of the actual price that they’re selling this vaccine for…

Want to know more click here go to health news source.

From -


Site Language

Popular Posts


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.